Develops antiviral therapies and treatments for other serious diseases, focusing on areas with high unmet medical needs.
Chimerix, Inc., a pioneering biopharmaceutical company headquartered in Durham, North Carolina, is dedicated to advancing treatments that significantly improve the lives of patients facing serious diseases. At the forefront of its portfolio is TEMBEXA (brincidofovir), a lipid conjugate that inhibits viral DNA synthesis. TEMBEXA is specifically developed as a medical countermeasure for smallpox, showcasing Chimerix's commitment to addressing critical public health needs.
In addition to TEMBEXA, Chimerix is actively pursuing clinical stage development programs that hold promise for treating various challenging conditions. These include ONC201, targeting tumors with the H3 K27M mutation in recurrent diffuse midline glioma patients. The company's pipeline also features ONC206, an imipridone that acts as a Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist, currently undergoing Phase I trials for solid tumors. ONC212, another imipridone agonist, focuses on orphan G protein-coupled receptors (GPCR) like GPR132, addressing solid tumors and hematological malignancies such as pancreatic cancer and leukemias. Aditionally, dociparstat sodium (DSTAT) inhibits proteins implicated in chemotherapy resistance in acute myeloid leukemia.
Founded in 2000, Chimerix has established strategic partnerships to bolster its research and commercialization efforts. These collaborations include agreements with Biomedical Advanced Research and Development Authority (BARDA) for brincidofovir's smallpox treatment, Cantex Pharmaceuticals, Inc. for glycosaminoglycan compounds, and SymBio Pharmaceuticals for various human indications of BCV. With a robust pipeline and a focus on innovation, Chimerix continues to push boundaries in biopharmaceutical research, aiming to make significant advancements in therapeutic options for patients worldwide.